ID   SUM225CWN
AC   CVCL_5593
SY   SUM-225CWN; SUM-225cwn; SUM 225CWN; SUM-225 Chest Wall Nodule; SUM-225; SUM 225; SUM225; Sum225; 225CWN
DR   BTO; BTO:0005478
DR   CLO; CLO_0009920
DR   EFO; EFO_0001244
DR   ArrayExpress; E-TABM-157
DR   cancercelllines; CVCL_5593
DR   Cosmic; 904392
DR   Cosmic; 1046960
DR   Cosmic; 1136359
DR   Cosmic; 1287900
DR   Cosmic; 1289415
DR   Cosmic; 1460242
DR   DepMap; ACH-001397
DR   GEO; GSM320177
DR   GEO; GSM847437
DR   GEO; GSM847504
DR   GEO; GSM844709
DR   GEO; GSM844710
DR   GEO; GSM1053732
DR   GEO; GSM1172995
DR   GEO; GSM1172901
DR   IARC_TP53; 24360
DR   LINCS_HMS; 51085
DR   LINCS_LDP; LCL-2070
DR   PharmacoDB; SUM225CWN_1516_2019
DR   Progenetix; CVCL_5593
DR   SLKBase; 284
DR   Wikidata; Q54970848
RX   PubMed=10424408;
RX   PubMed=10604729;
RX   PubMed=10969801;
RX   PubMed=15677628;
RX   PubMed=16397213;
RX   PubMed=16541312;
RX   PubMed=17157791;
RX   PubMed=19593635;
RX   PubMed=23151021;
RX   PubMed=23401782;
RX   PubMed=23601657;
RX   PubMed=24176112;
RX   PubMed=25960936;
RX   PubMed=28196595;
RX   PubMed=32715085;
WW   https://bioivt.com/sum-breast-cancer-cell-lines/
WW   https://www.synapse.org/#!Synapse:syn2346643/wiki/62255
WW   https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: GrayJW breast cancer cell line panel.
CC   Part of: MD Anderson Cell Lines Project.
CC   Doubling time: 73.20 hours (GrayJW panel).
CC   HLA typing: A*01:01,02:01; B*08:01,39:01; C*07:01,12:03; DQB1*05:01,05:01; DRB1*16:05,16:05 (PubMed=25960936).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu265Pro (c.794T>C); ClinVar=VCV000245777; Zygosity=Unspecified (PubMed=16541312).
CC   Omics: Array-based CGH.
CC   Omics: Deep exome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: miRNA expression profiling.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: Metastatic; Chest wall; UBERON=UBERON_0016435.
ST   Source(s): DepMap
ST   Amelogenin: X
ST   CSF1PO: 10,12
ST   D13S317: 12
ST   D16S539: 11
ST   D18S51: 14
ST   D21S11: 30,33.2
ST   D3S1358: 16,19
ST   D5S818: 11,13
ST   D7S820: 8,9
ST   D8S1179: 15
ST   FGA: 24
ST   Penta D: 12
ST   Penta E: 10,12
ST   TH01: 7,9.3
ST   TPOX: 8,11
ST   vWA: 16,17
DI   NCIt; C4194; Invasive breast carcinoma of no special type
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   56Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 32
//
RX   PubMed=10424408; DOI=10.1023/A:1006135331912;
RA   Ignatoski K.M.W., Ethier S.P.;
RT   "Constitutive activation of pp125fak in newly isolated human breast
RT   cancer cell lines.";
RL   Breast Cancer Res. Treat. 54:173-182(1999).
//
RX   PubMed=10604729; DOI=10.1038/sj.bjc.6695007;
RA   Forozan F., Veldman R., Ammerman C.A., Parsa N.Z., Kallioniemi A.,
RA   Kallioniemi O.-P., Ethier S.P.;
RT   "Molecular cytogenetic analysis of 11 new breast cancer cell lines.";
RL   Br. J. Cancer 81:1328-1334(1999).
//
RX   PubMed=10969801;
RA   Forozan F., Mahlamaki E.H., Monni O., Chen Y.-D., Veldman R., Jiang Y.,
RA   Gooden G.C., Ethier S.P., Kallioniemi A., Kallioniemi O.-P.;
RT   "Comparative genomic hybridization analysis of 38 breast cancer cell
RT   lines: a basis for interpreting complementary DNA microarray data.";
RL   Cancer Res. 60:4519-4525(2000).
//
RX   PubMed=15677628; DOI=10.1093/carcin/bgi032;
RA   Gorringe K.L., Chin S.-F., Pharoah P.D.P., Staines J.M., Oliveira C.,
RA   Edwards P.A.W., Caldas C.;
RT   "Evidence that both genetic instability and selection contribute to
RT   the accumulation of chromosome alterations in cancer.";
RL   Carcinogenesis 26:923-930(2005).
//
RX   PubMed=16397213; DOI=10.1158/0008-5472.CAN-05-2853;
RA   Elstrodt F., Hollestelle A., Nagel J.H.A., Gorin M., Wasielewski M.,
RA   van den Ouweland A., Merajver S.D., Ethier S.P., Schutte M.;
RT   "BRCA1 mutation analysis of 41 human breast cancer cell lines reveals
RT   three new deleterious mutants.";
RL   Cancer Res. 66:41-45(2006).
//
RX   PubMed=16541312; DOI=10.1007/s10549-006-9186-z;
RA   Wasielewski M., Elstrodt F., Klijn J.G.M., Berns E.M.J.J., Schutte M.;
RT   "Thirteen new p53 gene mutants identified among 41 human breast cancer
RT   cell lines.";
RL   Breast Cancer Res. Treat. 99:97-101(2006).
//
RX   PubMed=17157791; DOI=10.1016/j.ccr.2006.10.008;
RA   Neve R.M., Chin K., Fridlyand J., Yeh J., Baehner F.L., Fevr T.,
RA   Clark L., Bayani N., Coppe J.-P., Tong F., Speed T., Spellman P.T.,
RA   DeVries S., Lapuk A., Wang N.J., Kuo W.-L., Stilwell J.L., Pinkel D.,
RA   Albertson D.G., Waldman F.M., McCormick F., Dickson R.B.,
RA   Johnson M.D., Lippman M.E., Ethier S.P., Gazdar A.F., Gray J.W.;
RT   "A collection of breast cancer cell lines for the study of
RT   functionally distinct cancer subtypes.";
RL   Cancer Cell 10:515-527(2006).
//
RX   PubMed=19593635; DOI=10.1007/s10549-009-0460-8;
RA   Hollestelle A., Nagel J.H.A., Smid M., Lam S., Elstrodt F.,
RA   Wasielewski M., Ng S.S., French P.J., Peeters J.K., Rozendaal M.J.,
RA   Riaz M., Koopman D.G., ten Hagen T.L.M., de Leeuw B.H.C.G.M.,
RA   Zwarthoff E.C., Teunisse A., van der Spek P.J., Klijn J.G.M.,
RA   Dinjens W.N.M., Ethier S.P., Clevers H.C., Jochemsen A.G.,
RA   den Bakker M.A., Foekens J.A., Martens J.W.M., Schutte M.;
RT   "Distinct gene mutation profiles among luminal-type and basal-type
RT   breast cancer cell lines.";
RL   Breast Cancer Res. Treat. 121:53-64(2010).
//
RX   PubMed=23151021; DOI=10.1186/1471-2164-13-619;
RA   Grigoriadis A., Mackay A., Noel E., Wu P.-J., Natrajan R., Frankum J.,
RA   Reis-Filho J.S., Tutt A.;
RT   "Molecular characterisation of cell line models for triple-negative
RT   breast cancers.";
RL   BMC Genomics 13:619.1-619.14(2012).
//
RX   PubMed=23401782; DOI=10.1155/2013/872743;
RA   Barnabas N., Cohen D.;
RT   "Phenotypic and molecular characterization of MCF10DCIS and SUM breast
RT   cancer cell lines.";
RL   Int. J. Breast Cancer 2013:872743.1-872743.16(2013).
//
RX   PubMed=23601657; DOI=10.1186/bcr3415;
RA   Riaz M., van Jaarsveld M.T.M., Hollestelle A.,
RA   Prager-van der Smissen W.J.C., Heine A.A.J., Boersma A.W.M., Liu J.-J.,
RA   Helmijr J.C.A., Ozturk B., Smid M., Wiemer E.A.C., Foekens J.A.,
RA   Martens J.W.M.;
RT   "miRNA expression profiling of 51 human breast cancer cell lines
RT   reveals subtype and driver mutation-specific miRNAs.";
RL   Breast Cancer Res. 15:R33.1-R33.17(2013).
//
RX   PubMed=24176112; DOI=10.1186/gb-2013-14-10-r110;
RA   Daemen A., Griffith O.L., Heiser L.M., Wang N.J., Enache O.M.,
RA   Sanborn Z., Pepin F., Durinck S., Korkola J.E., Griffith M., Hur J.S.,
RA   Huh N., Chung J., Cope L., Fackler M.J., Umbricht C.B., Sukumar S.,
RA   Seth P., Sukhatme V.P., Jakkula L.R., Lu Y.-L., Mills G.B., Cho R.J.,
RA   Collisson E.A., van 't Veer L.J., Spellman P.T., Gray J.W.;
RT   "Modeling precision treatment of breast cancer.";
RL   Genome Biol. 14:R110.1-R110.14(2013).
//
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893;
RA   Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.;
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:e954893.1-e954893.12(2014).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=32715085; DOI=10.1038/s41523-020-0173-z;
RA   Ethier S.P., Guest S.T., Garrett-Mayer E., Armeson K., Wilson R.C.,
RA   Duchinski K., Couch D., Gray J.W., Kappler C.S.;
RT   "Development and implementation of the SUM breast cancer cell line
RT   functional genomics knowledge base.";
RL   NPJ Breast Cancer 6:30.1-30.14(2020).
//